Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company dedicated to developing vaccines to prevent infectious diseases. Based in Gaithersburg, Maryland, with facilities in Rockville, Maryland, and Uppsala, Sweden, Novavax employs over 300 professionals focused on innovation in vaccine development.
Novavax leverages its proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant to create vaccines that stimulate strong immune responses. The company's product pipeline includes vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus. Additionally, their pipeline includes preclinical programs targeting various infectious diseases.
Recently, Novavax has made significant strides in COVID-19 vaccine development. The company announced that its Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) received Emergency Use Listing (EUL) from the World Health Organization (WHO). This listing expedites the regulatory approval process, enabling broader global distribution. The vaccine is also authorized in the U.S. and the European Union and is under review in other markets.
Novavax's updated COVID-19 vaccine can be stored at temperatures between 2 to 8 degrees Celsius and has a 12-month shelf life, simplifying logistics and reducing waste. This vaccine has shown efficacy against multiple variants, including BA.2.86, EG.5.1, and XBB.1.16.6.
In addition to their COVID-19 efforts, Novavax has entered a co-exclusive licensing agreement with Sanofi to enhance the distribution of their standalone adjuvanted COVID-19 vaccine and develop combination vaccines. This partnership highlights the company's commitment to leveraging its technology to address global health challenges.
Financially, Novavax has shown a strong performance with updated financial guidance for 2024. With over $1 billion in potential contract value for advance purchase agreements, Novavax is well-positioned to deliver on its commitments while focusing on expanding its product portfolio.
Overall, Novavax Inc. represents a significant player in the biotechnology sector, continuously pushing the boundaries of vaccine development to address pressing global health issues.
Novavax (Nasdaq: NVAX) has announced a significant agreement with Serum Institute of India to manufacture approximately 1 billion doses of its COVID-19 vaccine candidate, NVX-CoV2373, in 2021. This expands Novavax's global manufacturing capacity to over 2 billion doses annually when fully operational. The agreement establishes a robust supply chain, with production facilities across multiple continents, and supports Novavax's commitment to equitable vaccine distribution. The vaccine is currently in Phase 2 clinical trials, with Phase 3 trials anticipated soon.
Novavax (Nasdaq: NVAX) announced its participation in five investor conferences, highlighting its COVID-19 vaccine candidate NVX-CoV2373. Key events include:
- Citi 15th Annual BioPharma Virtual Conference on September 10, 2020
- H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, 9:30 a.m. ET
- Cantor Virtual Global Healthcare Conference on September 15, 2020, 11:20 a.m. ET
- Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, 12:30 p.m. ET
- Leerink CyberRx Series: Vaccine Forum on September 23, 2020, 9:00 a.m. ET
Replays will be available on Novavax's website.
Novavax (Nasdaq: NVAX) announced the publication of Phase 1 data for its COVID-19 vaccine candidate, NVX-CoV2373, in The New England Journal of Medicine. The results indicate a strong safety profile and superior antibody responses compared to human convalescent sera. Following positive Phase 1 results, multiple Phase 2 trials commenced in the US, Australia, and South Africa to further evaluate efficacy. The funding for the trial includes support from the Coalition for Epidemic Preparedness Innovations (CEPI). NVX-CoV2373 showcases a favorable product profile, with stability for easy storage.
Novavax (NVAX) has reached an agreement with the Canadian government to supply up to 76 million doses of its COVID-19 vaccine, NVX-CoV2373, set to start in the second quarter of 2021. The deal aims to ensure broad access to the vaccine, which is currently in multiple Phase 2 clinical trials, including a Phase 2b trial in South Africa. NVX-CoV2373 utilizes Novavax's proprietary Matrix-M™ adjuvant to enhance immune responses. The agreement will finalize subject to Health Canada's licensure of the vaccine.
Novavax (Nasdaq: NVAX) announced the enrollment of first volunteers in the Phase 2 clinical trial of its COVID-19 vaccine candidate, NVX-CoV2373. This trial aims to assess immunogenicity and safety, expanding the age range to include participants aged 60-84 years, who constitute about 50% of the trial population. The trial will enroll up to 1,500 volunteers across the U.S. and Australia, with preliminary efficacy evaluations as a secondary objective. Interim data is expected in Q4 2020, following encouraging Phase 1 results that showed robust antibody responses.
Novavax, Inc. (NASDAQ: NVAX) has announced the initiation of a Phase 2b clinical trial in South Africa for its COVID-19 vaccine candidate NVX-CoV2373. The trial, led by Professor Shabir Madhi, aims to assess the vaccine's efficacy with a $15 million grant from the Bill & Melinda Gates Foundation. Approximately 2,665 healthy adults and 240 medically stable, HIV-positive adults will participate. The trial infrastructure and seasonal COVID-19 transmission could allow for rapid evaluation of efficacy. If successful, the vaccine may be supplied to South Africa through Novavax's collaboration with the Serum Institute of India.
Novavax has signed an agreement with the UK government to supply 60 million doses of its COVID-19 vaccine, NVX-CoV2373, starting in Q1 2021. The partnership includes collaboration with FUJIFILM Diosynth Biotechnologies to manufacture the vaccine's antigen in the UK, with a capacity of up to 180 million doses annually. A Phase 3 clinical trial will assess the vaccine's efficacy, involving approximately 9,000 adults, slated to begin in Q3 2020. Novavax has received $2 billion in funding for its global vaccine program.
AGC Biologics has expanded its partnership with Novavax (NASDAQ: NVAX), enhancing the production of Matrix-M, the adjuvant for Novavax's coronavirus vaccine, NVX-CoV2373. The manufacturing will occur at AGC's facilities in Seattle and Copenhagen to ensure adequate supply for the U.S. and global markets. This development supports Novavax's urgent need to enhance vaccine availability in 2020 and 2021. Both companies acknowledge the critical role AGC plays in the supply chain for the coronavirus vaccine.
Novavax (NVAX) reported encouraging Phase 1 data for its COVID-19 vaccine, NVX-CoV2373, demonstrating superior neutralization levels and strong immune responses. The company secured $2 billion funding from CEPI, DoD, and OWS, enhancing its operational capacity and collaborations with Takeda and Serum Institute. Financial results show a significant revenue increase to $35.5 million for Q2 2020, compared to $3.4 million in Q2 2019, alongside a reduced net loss of $17.5 million. Novavax continues to strengthen its leadership team and expand manufacturing capabilities for vaccine production.
Novavax has partnered with Takeda to license its COVID-19 vaccine technology, NVX-CoV2373, for production and commercialization in Japan. The Government of Japan will fund Takeda for technology transfer and infrastructure setup, enabling the manufacture of over 250 million doses annually. Novavax will supply the proprietary Matrix-M adjuvant. The collaboration aims to enhance pandemic preparedness and expand vaccine availability in Japan, with Novavax set to receive milestone payments and a share of the vaccine proceeds.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
What is Novavax Inc. known for?
Where is Novavax Inc. headquartered?
What recent achievements has Novavax made?
What is the storage requirement for Novavax's COVID-19 vaccine?
Who are Novavax’s main partners?
What are the key products in Novavax's pipeline?
How does Novavax’s Matrix-M™ adjuvant work?
What financial performance is expected from Novavax in 2024?
Is Novavax's COVID-19 vaccine effective against variants?
What is the significance of Novavax's partnership with Sanofi?
